JPMorgan maintains Charles River Labs stock at Neutral on challenges

On Tuesday, JPMorgan reaffirmed its Neutral position on shares of Charles River Laboratories International, Inc. (NYSE:CRL) with a steady price target of $215.00. Currently trading at $178.02, the stock is hovering near its 52-week low, and according to InvestingPro analysis, appears undervalued based on its Fair Value assessment.

The reiteration followed an 8-K filing by Charles River Labs (NYSE:CRL), detailing its preliminary guidance for the year 2025. The company anticipates that its 2025 revenues will organically decline in a range similar to that estimated for 2024, suggesting a decrease of 4% to 3% compared to analysts' expectations of a 0.7% increase.

Charles River Labs expects Discovery (NASDAQ:WBD) Services and Alliances (DSA) trends to continue as they did in the second half of 2024, with limited demand from large pharmaceutical companies and stable to slightly improving demand from biotech companies. The firm also anticipates DSA pricing to negatively impact revenue in 2025.

Moreover, a decrease in commercial Contract Development and Manufacturing Organization (CDMO) revenue is projected to lower overall revenue growth by about 1% in 2025. Site consolidation efforts are also expected to create a revenue headwind of approximately 0.5% for the year.

The company noted that while demand for biotech remained stable in 2024 and showed year-over-year improvement, demand from large pharmaceutical companies stabilized in the second half of 2024.

Despite these challenges, InvestingPro data shows Charles River maintains a GOOD overall Financial Health Score, with particularly strong marks in profitability metrics. The company's P/E ratio stands at 23.67, while maintaining a healthy gross profit margin of 35.67%. Charles River Labs predicts these demand trends will persist into 2025.

Furthermore, the company has faced challenges with its CDMO business, including the termination of a contract by one commercial cell therapy customer and the expectation of reduced revenue from another this year. Despite these setbacks and the potential for an impairment of goodwill and long-lived assets in the CDMO segment, Charles River Labs remains confident in the long-term market opportunities for its CDMO business.

Foreign exchange rates are also expected to pose a headwind to reported revenue in 2025, exceeding 1%. On the profitability front, the company forecasts that adjusted Operating Profit Margin (OPM) will be slightly below the levels estimated for 2024, which were already guided to be just below the 2023 level of 20.3%, contrasting with a market consensus of a 19.6% adjusted OPM for 2025.

Investors are anticipated to closely watch the company's presentation at the JPMorgan conference, scheduled for 2:15 PM PT (5:15 PM ET) today, where further details regarding the preliminary guidance for 2025, demand trends in DSA, and additional information on the CDMO commercial headwinds will be addressed.

In other recent news, Charles River Laboratories has been the subject of multiple analyst notes. TD Cowen reaffirmed a Hold rating on the company's shares with a price target of $227, citing ongoing challenges that might delay a recovery until 2026.

Among these challenges are a decline in revenue due to factors such as pricing dynamics, consistent demand levels, the impact of site consolidation, the loss of a contract development and manufacturing organization (CDMO) commercial client, and a deceleration in CDMO demand.

In line with these developments, BofA Securities maintained a Neutral rating on Charles River Labs with a price target of $210. The company's preliminary forecast for fiscal year 2025 indicates continued sales challenges, with an anticipated revenue drop of 4.5%, equating to approximately $3.85 billion in sales. This falls short of consensus estimates of $4.07 billion by 5.5%. The adjusted earnings per share are projected to be around $9.50, as opposed to the Street's expectation of approximately $10.20.

Baird also maintained a Neutral rating on Charles River Labs but reduced its price target to $197 from $211. The company is focusing on cost management and capital deployment in the short term. TD Cowen also held a Hold rating but increased the price target to $227 from $203, following the company's third-quarter results.

Despite these challenges, Charles River Laboratories maintains a "GOOD" overall financial health score, with strong profitability metrics. These recent developments reflect analysts' cautious optimism about Charles River Laboratories' near-term prospects despite the expected revenue decline. These are the latest updates for Charles River Laboratories, providing investors with a snapshot of the company's current state.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.